Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). Twenty PBC patients on UDCA (13-15 mg/kg/day) therapy with an elevation of serum alkaline phosphatase at least twice the upper limit of normal were treated with oral moexipril 15 mg/day for one year. No significant changes in serum alkaline phosphatase (379 ± 32 vs. 379 ± 51), bilirubin (0.8 ± 0.1 vs. 0.9 ± 0.1), aspartate aminotransferase (60 ± 8 vs. 63 ± 9), and Mayo risk score (3.55 ± 0.2 vs. 3.62 ± 0.2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA.
- Angiotensin-converting enzyme inhibitor
- Primary biliary cirrhosis
- Ursodeoxycholic acid
ASJC Scopus subject areas